Practical insights for the management of patients with NDMM.
Case: A 54-Year-Old Woman with Newly Diagnosed Multiple Myeloma (NDMM)
Clinical Presentation:
Initial Clinical Workup and Diagnosis:
Treatment:
This is a video synopsis/summary of a Case-Based Peer Perspective featuring: Douglas Sborov, MD.
When it comes to newly diagnosed transplant-eligible multiple myeloma, the standard of care is now quadruplet induction. All patients should undergo stem cell collection and have a discussion regarding the potential utility of transplant. High-risk patients should receive doublet maintenance therapy following transplant. Relatively early discontinuation or dose reduction of steroids should be considered as they are not necessary long term, including in the maintenance setting. Risk stratification for clotting should occur at diagnosis, and most patients will require direct oral anticoagulant prophylaxis rather than aspirin alone to mitigate immunomodulatory drug-associated clot risk. Lastly, given the emergence of exciting novel therapies like chimeric antigen receptor T-cell and bispecific antibodies, coordination of care with an academic myeloma program should always be considered.
Video synopsis is AI-generated and reviewed by Targeted Oncology® editorial staff.
Khouri Discusses Selinexor Dosing and Management Approaches for R/R MM
July 22nd 2024During a Case-Based Roundtable® event, Jack Khouri, MD, and participants discussed the use of selinexor with dose modifications to manage toxicity in patients with relapsed/refractory multiple myeloma.
Read More
New Hope for Multiple Myeloma: Cilta-Cel Improves Overall Survival
July 2nd 2024The CARTITUDE-4 study that found that treatment with cilta-cel led to a statistically significant and clinically meaningful improvement in overall survival among patients with relapsed and lenalidomide-refractory multiple myeloma who received 1 to 3 prior lines of therapy.
Read More